Your browser is no longer supported. Please, upgrade your browser.
Reneo Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)- Insider Own14.20% Shs Outstand21.36M Perf Week-7.85%
Market Cap216.10M Forward P/E- EPS next Y-2.95 Insider Trans114.52% Shs Float3.56M Perf Month-1.60%
Income- PEG- EPS next Q-0.47 Inst Own75.10% Short Float31.65% Perf Quarter-7.53%
Sales- P/S- EPS this Y-56.50% Inst Trans- Short Ratio12.82 Perf Half Y-
Book/sh7.84 P/B1.02 EPS next Y7.20% ROA- Target Price- Perf Year-
Cash/sh6.18 P/C1.29 EPS next 5Y- ROE- 52W Range6.10 - 17.18 Perf YTD-42.55%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-53.55% Beta-
Dividend %- Quick Ratio51.30 Sales past 5Y- Gross Margin- 52W Low30.82% ATR1.10
Employees17 Current Ratio51.30 Sales Q/Q- Oper. Margin- RSI (14)46.24 Volatility11.34% 16.40%
OptionableNo Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume0.77 Prev Close7.76
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume87.84K Price7.98
Recom1.30 SMA20-6.17% SMA50-6.40% SMA200-19.51% Volume67,227 Change2.84%
May-04-21Initiated SVB Leerink Outperform $25
May-04-21Initiated Piper Sandler Overweight $45
May-04-21Initiated Jefferies Buy $24
Sep-09-21 09:12AM  
Aug-11-21 05:55AM  
Jul-28-21 08:00AM  
Jul-12-21 09:30AM  
Jul-09-21 08:00AM  
Jul-07-21 08:00AM  
Jun-29-21 08:00AM  
May-20-21 06:00AM  
May-19-21 06:00AM  
Apr-13-21 08:14AM  
Apr-09-21 12:32PM  
Apr-08-21 09:42PM  
Reneo Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. The company was incorporated in 2014 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Jindal Vineet R.Chief Financial OfficerAug 25Buy7.445,00037,1765,000Aug 26 05:54 PM
FLESHER GREGORY J.President and CEOAug 25Buy8.008,00064,0008,000Aug 26 05:52 PM
Cruse MichaelSenior VP-Corporate OperationsAug 25Buy7.452,50018,6162,500Aug 26 05:51 PM
Muralidhar BaliDirectorJul 14Buy8.50111,736949,7562,073,957Jul 15 05:34 PM
Johnson Wendy S.Chief Development OfficerJul 14Sale8.50111,736949,7560Jul 15 05:33 PM
Johnson Wendy S.Chief Development OfficerJul 08Option Exercise1.97111,736220,120111,736Jul 09 06:52 PM
Muralidhar BaliDirectorJun 23Buy9.2820,710192,2451,962,221Jun 25 09:00 AM
Muralidhar BaliDirectorJun 22Buy8.7214,615127,4871,941,511Jun 23 08:33 AM
Muralidhar BaliDirectorJun 21Buy9.0332,659294,9271,926,896Jun 23 08:33 AM
Muralidhar BaliDirectorJun 08Buy9.5016,605157,7091,894,237Jun 10 09:00 AM
Muralidhar BaliDirectorJun 04Buy9.422572,4221,877,632Jun 07 08:53 AM
Muralidhar BaliDirectorJun 03Buy9.2512,100111,9431,877,375Jun 07 08:53 AM
Muralidhar BaliDirectorMay 28Buy9.50141331,865,275Jun 02 10:37 AM
Muralidhar BaliDirectorMay 27Buy9.261,12010,3691,865,261May 28 04:10 PM
Muralidhar BaliDirectorMay 26Buy9.385,91555,4951,864,141May 28 04:10 PM
New Enterprise Associates 15, 10% OwnerApr 13Buy15.00666,6669,999,9904,785,494Apr 15 06:16 PM
O'Donnell NiallDirectorApr 13Buy15.00200,0003,000,0002,063,713Apr 15 04:16 PM
Muralidhar BaliDirectorApr 13Buy15.00200,0003,000,0001,858,226Apr 15 04:15 PM
Novo Holdings A/S10% OwnerApr 13Buy15.00666,6669,999,9903,430,377Apr 14 04:44 PM
RiverVest Venture Fund III, L.10% OwnerApr 09Buy15.00200,0003,000,0002,409,220Apr 13 05:54 PM